June 20: The dialogue will be held on Tuesday, June 20, 2023 at the Suzhou adock Innovation Center (1F, No. 328, Xinghu Street, Suzhou Industrial Park, SIP).

April 27: In the Salon of Suzhou Industrial Park Science and Technology Innovation Intellectual Property Day, Founder & Managing Partner of SR Biomedical gave a keynote speech on how to extend the life cycle of pharmaceuticals through patenting strategies. Dronedarone is an antiarrhythmic drug for patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), to reduce the risk of hospitalization, for patients with recent episodes of AF/AFL and associated cardiovascular risk factors, and for patients in sinus rhythm or with rewarming of the heart rhythm. Approved for marketing in the U.S. in 2009 after nearly 20 years of research and development, its compound patent expired in 2011. However, through an effective patenting strategy, its protection was extended to 2029/2031. What kind of patent strategy and layout did the originator drug company use to protect the marketed drug for more than 20 years? The founder of SR Biomedical shares this patent protection success story.

April 27: In the Salon of Suzhou Industrial Park Science and Technology Innovation Intellectual Property Day, Founder & Managing Partner of SR Biomedical gave a keynote speech on how to extend the life cycle of pharmaceuticals through patenting strategies. Dronedarone is an antiarrhythmic drug for patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), to reduce the risk of hospitalization, for patients with recent episodes of AF/AFL and associated cardiovascular risk factors, and for patients in sinus rhythm or with rewarming of the heart rhythm. Approved for marketing in the U.S. in 2009 after nearly 20 years of research and development, its compound patent expired in 2011. However, through an effective patenting strategy, its protection was extended to 2029/2031. What kind of patent strategy and layout did the originator drug company use to protect the marketed drug for more than 20 years? The founder of SR Biomedical shares this patent protection success story.